INNOCARE PHARMA (09969.HK) +0.660 (+4.441%) Short selling $42.90M; Ratio 44.967% announced its 2025 annual results, reporting revenue of RMB2.375 billion, representing a year-on-year increase of 135.3%. The company recorded a net profit of RMB642 million, compared to a loss of RMB441 million in the previous year, turning from loss to profit; earnings per share were RMB0.38. No final dividend was declared. (de/d)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.)
AASTOCKS Financial News